Korte en heterogene respons van crizotinib

Bronnen:

1. Van Veggel B, De Langen AJ, Hashemi S, et al. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. Lung Cancer. 2018;124:317-9.